Last update Aug. 6, 2017
Very Low Risk
Alpha-glucosidase inhibitor which acts within the gastrointestinal tract without being absorbed, reducing intestinal absorption of glucose. Very low risk of hypoglycemia in monotherapy.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (moderately elevated molecular weight and very low intestinal absorption) make it unlikely that it would pass to breast milk in significant amounts (Serrano 2014, Everett 1997).
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM